PharmTech Drug Digest 11.20
News|Articles|April 10, 2014

uniQure Announces Management Changes

Author(s)Melanie Sena

uniQure appoints a new COO and vice president, Medical affairs.

uniQure, a human gene therapy company, reported the appointment of Eric Goossens as its new COO. Goossens has 15 years of experience in management and leadership for technology-based companies, including the biopharmaceutical industry.

In addition, uniQure appointed Deya Corzo, MD, as vice president, Medical Affairs for the US as of April 1, 2014. Goossens joins uniQure from Dätwyler Pharma Packaging Belgium N.V where he was site director for three years. Corzo previously worked at Celgene, as executive director, Medical Affairs/Oncology from 2012 to 2014.

Source: uniQure


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.